Metachromatic Leukodystrophy and related lysosomal storage disorders
Orchard Therapeutics (Europe) Limited supports clinical research in Metachromatic Leukodystrophy, including late juvenile MLD and broader ARSA deficiency manifestations. The funded studies focus on neurological outcomes, disease progression, and restoration of enzyme activity in affected tissues.
- MLD
- Late juvenile MLD
- Motor impairment
- Residual ARSA activity
Research activity in this area is centered on gene therapy approaches designed for inherited neurodegenerative disease.
Mucopolysaccharidosis type I and Hurler syndrome
The sponsor funds studies in Mucopolysaccharidosis type I, including the severe childhood form known as Hurler syndrome. These trials examine treatment options aimed at addressing the underlying metabolic defect and supporting clinical benefit in pediatric patients.
- MPS-IH
- Hurler syndrome
- IDUA gene
- Pediatric lysosomal disease
Clinical interest in this domain includes autologous hematopoietic stem cell approaches for inherited metabolic disorders.
Hematopoietic stem cell gene therapy
Orchard Therapeutics focuses on hematopoietic stem cell-based gene therapy programs that use genetically modified autologous cells to treat inherited diseases. The clinical portfolio includes investigations of cell-enriched products and lentiviral vector-enabled gene delivery.
- Autologous CD34+ cells
- HSPC transduction
- Lentiviral vector
- Cell-based gene transfer
These studies reflect a strong therapeutic interest in correcting inherited enzyme deficiencies through ex vivo cellular engineering.
Neurological and motor function outcomes
The sponsor’s trials place emphasis on neurological disease burden, including central nervous system involvement, peripheral nervous system involvement, and changes in functional performance. Outcomes include clinical measures of motor impairment and disease-related disability in children and young people.
- Clinical motor impairment
- GMFM scoring
- Neurological progression
- Functional disability
This area links the sponsor’s work to disorders where preserving movement, coordination, and neurological function is central to treatment evaluation.
